Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.
The FDA has approved the combination of ibrutinib and obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ian W. Flinn, MD, PhD, discusses the potential impact of duvelisib on patients with chronic lymphocytic leukemia.
Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.
The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.
Matthew S. Davids, MD, MMSc, discusses the clinical implications of the DUO trial in patients with chronic lymphocytic leukemia.
John F. Seymour, MBBS, PhD, discusses the clinical implications of the MURANO trial and highlights the feasibility for time-limited therapy and its benefits for patients with chronic lymphocytic leukemia.
Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.
Patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia achieved objective response rates as high as 100% with either of 2 doses of the BTK inhibitor acalabrutinib, results of an open-label phase II trial showed.
The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.